The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAllergy Thera. Share News (AGY)

Share Price Information for Allergy Thera. (AGY)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.875
Bid: 2.75
Ask: 3.00
Change: 0.00 (0.00%)
Spread: 0.25 (9.091%)
Open: 2.875
High: 3.00
Low: 2.875
Prev. Close: 2.875
AGY Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: H&T plans raise; Joules turnaround continues

Thu, 29th Sep 2022 22:08

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

----------

Dolphin Capital Investors Ltd - British Virgin Islands-based investor in high-end resort developments in the eastern Mediterranean - Sells entire interest in the One&Only at Kea Island project, netting EUR17.9 million. Owns 67% of Single Purpose Vehicle Ten Ltd which, in turn, indirectly owns 50% of One&Only, giving it effective equity interest of 33%.

----------

H&T Group PLC - Surrey, England-based pawnbroker - Plans to raise GBP16.9 million from issue to institutional investors at 425 pence each. Says proceeds of issue will go towards growing its pledge book, given strong demand, and to fund the expansion of the store estate through the opening of up to a further 20 new stores in 2023. Notes pledge book ended August at GBP89.6 million, rising from GBP50.2 million at June 30.

----------

Joules Group PLC - Leicestershire, England-based country lifestyle retailer - Notes it is making "good progress" in developing its turnaround plan, which is focuses on "driving higher profitability". "The company continues to make good progress on its simplification agenda and cost management process. Interpath Advisory is assisting the board with an initial assessment of certain elements as part of the development of this turnaround plan," it adds. Continues to assess its ongoing financing requirements, including a possible equity raise.

----------

Allergy Therapeutics PLC - Sussex-based biotechnology firm focused on allergy vaccines - In financial year ended June 30, sinks to pretax loss of GBP12.7 million versus GBP3.7 million profit the year prior. Revenue drops to GBP72.8 million from GBP84.3 million. Research & development costs grows to GBP15.7 million from GBP12.9 million. Notes a "strategic streamlining" of older products to focus on high value growth products. Chief Executive Manuel Llobet adds: "While market conditions remain challenging for many companies, our leading core European commercial business has been resilient."

----------

Gulf Marine Services PLC - United Arab Emirates-based lift boat company - Signs improved contract, with a total duration of 72 months, for both an E-Class and K-Class vessel with an unnamed national oil company in MENA. The contract will come into effect in October 2022. Second contract win of the week, following new contract for an E Class vessel with an unnamed client in the Middle East and North Africa region.

----------

Thungela Resources Ltd - South Africa-based thermal coal exporter - Responds to an article from Bloomberg titled 'Top Coal Miners Consider Bids for South African Renewables Firm' which suggest Thungela is considering a bid for Actis LLP's BTE Renewables. Calls the article "factually incorrect". Confirms that it is not considering the acquisition of "any" renewables business". "We are not focused on diversification into the renewable energy sector," it says. Says current plans are limited to the installation of a 137-kilowatt solar plant at the eMalaheni water reclamation plant in South Africa and studies for a 4-megawatt solar photovoltaic plant at its Zibulo colliery.

----------

By Paul McGowan; paulmcgowan@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
27 Mar 2024 16:13

EARNINGS AND TRADING: Solid State ups outlook; Quartix trading in line

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
27 Mar 2024 11:02

AIM WINNERS & LOSERS: Norman Broadbent profit swing on rising revenue

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
12 Mar 2024 14:06

Allergy Therapeutics starts dosing patients in peanut allergy trial

(Alliance News) - Allergy Therapeutics PLC on Tuesday said it has commenced subcutaneous dosing of peanut allergic patients in its phase 1/2a Protect trial.

Read more
1 Mar 2024 15:49

UK shareholder meetings calendar - next 7 days

Monday 4 March 
Ascent Resources PLCGM re bonus issue of preference shares
JPMorgan Emerging Europe, Middle East & Africa Securities PLCAGM
Lexington Gold LtdAGM
Tuesday 5 March 
Ajax Resources PLCGM re extension of investment mandate
Beowulf Mining PLCGM re capital raise
CC Japan Income & Growth Trust PLCAGM
Driver Group PLCAGM
Edinburgh Worldwide Investment Trust PLCAGM
Jersey Electricity PLCAGM
Wednesday 6 March 
Ecofin Global Utilities & Infrastructure Trust PLCAGM
Mila Resources PLCAGM
Paragon Banking Group PLCAGM
Thursday 7 March 
Asia Strategic Holdings LtdAGM
CT UK Capital & Income Investment Trust PLCAGM
Henderson Opportunities Trust PLCAGM
XPS Pensions Group PLCGM re directors' remuneration policy 2024
Friday 8 March 
Allergy Therapeutics PLCAGM
All Things Considered Group PLCAGM
Chenavari Toro Income Fund LtdAGM
Neo Energy Metals PLCAGM
Schroder UK Mid Cap Fund PLCAGM
Silverwood Brands PLCGM re proposed share capital reduction
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
14 Feb 2024 10:22

Allergy Therapeutics forecasts revenue drop but trials going well

(Alliance News) - Allergy Therapeutics PLC on Wednesday said revenue decreased in its latest half year, and expects to require further funding soon.

Read more
5 Feb 2024 14:09

TRADING UPDATES: Alliance Pharma appoints chair; FireAngel sales down

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
30 Jan 2024 10:38

Allergy Therapeutics resumes trading on AIM; annual revenue plunges

(Alliance News) - Allergy Therapeutics PLC on Tuesday resumed trading on AIM after the release of its annual results.

Read more
27 Dec 2023 14:17

IN BRIEF: Allergy Therapeutics amends facility, plans warrant issue

Allergy Therapeutics PLC - Sussex-based biotechnology company specialising in allergy vaccines - Shares rise as firm enters amendment to the facility agreement it reached in early April with SkyGem Acquisition Ltd and Southern Fox Investments Ltd. Deal provides Allergy Therapeutics with a GBP40 million secured loan facility of which GBP32.5 million is uncommitted. Facility is available to drawdown between January 15 and the same day in 2026, with interest payable semi-annually at 12% per year and a January 15, 2027 repayment date.

Read more
15 Dec 2023 21:09

EARNINGS AND TRADING: Redx full year revenue tumbles; loss widens

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Friday and not separately reported by Alliance News:

Read more
13 Dec 2023 10:11

Allergy Therapeutics shares jump as hails grass allergy jab data

(Alliance News) - Allergy Therapeutics PLC on Wednesday said that phase-3 trials of its grass allergy injection yielded positive results, moving the product closer to market entry.

Read more
13 Dec 2023 09:55

AIM WINNERS & LOSERS: Impellam climbs on GBP483 million takeover offer

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
11 Dec 2023 07:41

LONDON BRIEFING: GSK drug gets EU endorsement; Begbies backs outlook

(Alliance News) - London's FTSE 100 is called to open a touch lower on Monday, kicking off the week with some slight trepidation after Friday's hotter-than-expected US jobs report which offered the dollar some respite.

Read more
14 Nov 2023 11:56

Allergy Therapeutics says allergy therapy trial meets primary endpoint

(Alliance News) - Allergy Therapeutics PLC on Tuesday said that a trial evaluating the efficacy of its subcutaneous allergen-specific immunotherapy candidate has met its primary endpoint.

Read more
14 Nov 2023 10:59

AIM WINNERS & LOSERS: Renalytix revenue halves; DP Poland trades well

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.

Read more
6 Nov 2023 12:33

IN BRIEF: Allergy Therapeutics extends cash runway until end of 2023

Allergy Therapeutics PLC - West Sussex, England-based commercial biotechnology company - Says it continued to work on initiatives to improve cost control and manage working capital alongside trading broadly in line with expectations for the current financial year to date. Says it has extended its cash runway and anticipates to require additional funding by the end of December. Further, says discussions with some major shareholders regarding a subscription and open offer announced in October have progressed. Says that the pivotal phase 3 grass G306 modified allergen tyrosine adsorbed monophosphoryl lipid A trial remains on track to report interim results this month. Via G306, the company aims to release an immunotherapy for grass allergy.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.